AbCellera Biologics (ABCL) Payables (2020 - 2026)

AbCellera Biologics has reported Payables for 7 years, with the latest figure at $39.6 million in Q1 2026.

• For the quarter ending Q1 2026, Payables fell 17.33% year-over-year to $39.6 million; the trailing twelve-month figure through Mar 2026 stood at $39.6 million (down 17.33% YoY), and the FY2025 full-year result was $50.8 million, down 7.68% from the prior year.
• Payables for Q1 2026 stood at $39.6 million, down from $50.8 million in the prior quarter.
• The five-year high for Payables was $55.0 million in Q4 2024, with the low at $24.4 million in Q2 2022.
• Historically, Payables has averaged $43.2 million across 5 years, with a median of $47.8 million in 2025.
• Annual changes were most pronounced in 2023 — Payables soared 114.82% — and 2026, when it slipped 17.33%.
• AbCellera Biologics' Payables stood at $52.5 million in 2022, then slipped by 5.56% to $49.6 million in 2023, then increased by 10.94% to $55.0 million in 2024, then fell by 7.68% to $50.8 million in 2025, then decreased by 22.11% to $39.6 million in 2026.
• The last three Payables figures came in at $39.6 million (Q1 2026), $50.8 million (Q4 2025), and $53.1 million (Q3 2025), per Business Quant data.